TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07214571: A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Sponsor: Shionogi · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 192 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,499,400

Unlock Full NCT07214571 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07214571 Rescue Dossier →